QT prolongation in the intensive care unit: commonly used medications and the impact of drug–drug interactions

Bibliography

• Romac DR, Albertson TE. Drug interactions in the intensive care unit. Clin Chest Med 1999;20(2):385-99
   PubMed Web of Science ®Google Scholar
• Smithburger PL, Kane-Gill SL, Benedict NJ, Significance of drug-drug interactions in cardiac intensive care units. Crit Care Med 2010;37(Suppl 12):A460
   Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome p450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29(6):687-710
   PubMed Web of Science ®Google Scholar
• Köhler GI, Bode-Böger SM, Busse R, Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38:504-13
   PubMed Web of Science ®Google Scholar
• Hansten PD, Horn JR. Drug interactions analysis and management. Facts and comparisons. St. Louis, MO;1999
   Google Scholar
• Kopp BJ, Erstad BL, Allen ME, Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med 2006;34:415-25
   PubMed Web of Science ®Google Scholar
• Krishnan V, Murray P. Pharmacologic issues in the critically ill. Clin Chest Med 2003;24:671-88
   PubMed Web of Science ®Google Scholar
• Kane-Gill SL, Weber RJ. Principles and practices of medication safety in the ICU. Crit Care Clin 2006;22(2):273-90
   PubMed Web of Science ®Google Scholar
• Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharm Sci 2005;8:602-25
   PubMed Web of Science ®Google Scholar
• Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 2004;5:235-43
   PubMed Web of Science ®Google Scholar
• Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 2008;65:1029-38
   PubMed Web of Science ®Google Scholar
• Harrigan EP, Miceli JJ, Anziano R, A randomized evaluation of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9
   PubMed Web of Science ®Google Scholar
• Sadanaga T, Sadanaga F, Yao H, Fujishima M. Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: significance of bradycardia-dependent QT prolongation. J Electrocardiol 2004;37(4):267-73
   PubMed Web of Science ®Google Scholar
• Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000;18(2):227-9
   PubMed Web of Science ®Google Scholar
• Allen LaPointe NM, Curtis LH, Chan KA, Frequency of high risk use of QT prolonging medications. Pharmacepidemiol Drug Saf 2006;15:361-8
   Web of Science ®Google Scholar
• Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003;10:452-7
   PubMedGoogle Scholar
• Freeman BD, Dixon DJ, Coopersmith CM, Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiol Drug Saf 2008;17:971-81
   PubMed Web of Science ®Google Scholar
• Zeltser D, Justo D, Halkin A, Torsades de pointes due to noncardiac drugs most patients have easily identifiable risk factors. Medicine 2003;82:282-90
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Pettersson M, Meyboom RH, Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005;26:590-7
   PubMed Web of Science ®Google Scholar
• Kao LW, Furbee RB. Drug-induced Q-T prolongation. Med Clin N Am 2005;89:1125-44
   PubMed Web of Science ®Google Scholar
• Anderson ME, Al-Khatib SM, Roden DM, Califf RM. Duke Clinical Research Institute/American Heart Journal expert meeting on repolarization C. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002;144(5):769-81
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, LaPointe NM, Kramer JM, What clinicians should know about the QT interval. JAMA 2003;289(16):2120-7
   PubMed Web of Science ®Google Scholar
• Shah RR. Drug induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fundam Clin Pharmacol 2002;16:147-56
   PubMed Web of Science ®Google Scholar
• Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-22
   PubMed Web of Science ®Google Scholar
• Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23(7):881-908
   PubMed Web of Science ®Google Scholar
• Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62(11):1649-71
   PubMed Web of Science ®Google Scholar
• Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labeling. Drug Saf 2001; 24:323-51
   PubMed Web of Science ®Google Scholar
• Malik M, Farbom P, Batchvarov V, Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction fot eh QT interval. Heart 2002;87:220-8
   PubMed Web of Science ®Google Scholar
• Batchvarov VN, Ghuran A, Smetana P, QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002;282:H2356-63
   PubMed Web of Science ®Google Scholar
• Chan A, Isbister GK, Kirkpatrick CMJ, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. Q J Med 2007;100:609-15
   Google Scholar
• Isbister GK, Calver L, Gorp FV, Inter-rate reliability of manual QT measurement and prediction of abnormal QT, HR pairs. Clin Toxicol 2009;27:884-8
   Google Scholar
• Fossa AA, Wisialowski T, Magnano A, Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 2005;312:1-11
   PubMed Web of Science ®Google Scholar
• Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. Drugs 1994;47:51-65
   PubMed Web of Science ®Google Scholar
• De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001;57(3):185-209
   PubMed Web of Science ®Google Scholar
• Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89(11):1363-72
   PubMed Web of Science ®Google Scholar
• Splawski I, Shen J, Timothy KW, Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102(10):1178-85
   PubMed Web of Science ®Google Scholar
• El-Sherif N, Turitto G. Torsade de pointes. Current Opin Cardiol 2003;18(1):6-13
   PubMed Web of Science ®Google Scholar
• El-Sherif N, Turottio G. Torsade de Pointes. In: Zipes DP, Jalite J, editors, Cardiac electrophysiology, from cell to bedside. 4th edition. WB Saunders, Philadelphia; 2004. p. 689-99
   Google Scholar
• Sanguinetti MC. Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Ann NY Acad Sci 1999;868:406-13
   PubMed Web of Science ®Google Scholar
• Roden DM, Balser JR, George AL Jr, Anderson ME. Cardiac ion channels. Ann Rev Physiol 2002;64:431-75
   PubMed Web of Science ®Google Scholar
• Sudden Arrhythmia Death Syndromes Foundation. The long QT syndrome. SADS Foundation. Available from: www.sads.org
   Google Scholar
• Sakaguchi T Itoh H, Ding WG, Hydroxyzine, a first generation H1-receptor antagonist, inhibits human ether-a-go-go–related gene (HERG) current and causes syncope in a patient with the herg mutation. J Pharmacol Sci 2008;108(4):462-71
   PubMed Web of Science ®Google Scholar
• De Pointi F, Poluzzi E, Cavalli A, Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25(4)263-86
   PubMed Web of Science ®Google Scholar
• Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64(10):1091-124
   PubMed Web of Science ®Google Scholar
• Benoit SR, Mendelsohn AB, Nourjah P, Risk factors for prolonged QTc among US adults: third national health and nutrition examination survey. Eur J Cardiovasc Prev Rehabil 2005;12:363-8
   PubMed Web of Science ®Google Scholar
• Esposito K, Marfella R, Gualdiero P, Sympathovagal balance, nighttime blood pressure, and QT intervals in normotensive obese women. Obes Res 2003;11:653-9
   PubMedGoogle Scholar
• Papaioannou A, Michaloudis D, Fraidakis O, Effects of weight loss on QT interval in morbidly obese patients. Obes Surg 2003;13:869-73
   PubMed Web of Science ®Google Scholar
• Frank S, Colliver JA, Frank A. The electrocardiogram in obesity: statistical analysis of 1,029 patients. J Am Coll Cardiol 1986;7:295-9
   PubMed Web of Science ®Google Scholar
• Brown DW, Giles WH, Greenlund KJ, Impaired fasting glucose, diabetes mellitus, and cardiovascular disease risk factors are associated with prolonged QT duration. Results from the third national health and nutrition examination survey. J Cardiovasc Risk 2001;8:227-33
   PubMedGoogle Scholar
• El-Gamal A, Gallagher D, Nawras A, Effects of obesity on QT, RR and QTc intervals. Am J Cardiol 1995;75:956-9
   PubMed Web of Science ®Google Scholar
• Khechinashvili G, Asplund K. Electrocardiographic changes in patients with acute stroke: a systematic review. Cerebrovasc Dis 2002;14:67-76
   PubMed Web of Science ®Google Scholar
• Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 1998;73:175-87
   PubMedGoogle Scholar
• Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005;2:507-17
   PubMed Web of Science ®Google Scholar
• Napolitano C, Priori SG, Schwartz PJ, Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005;294:2975-80
   PubMed Web of Science ®Google Scholar
• Splawski I, Shen J, Timothy KW, Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178-85
   PubMed Web of Science ®Google Scholar
• Medeiros-Domingo A, Kaku T, Tester DJ, SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 2007;116:134-42
   PubMed Web of Science ®Google Scholar
• Yang P, Kanki H, Drolet B, Allelic variants in long-QT disease in patients with drug-associated torsades de pointes. Circulation 2002;105:1943-8
   PubMed Web of Science ®Google Scholar
• Moro C, Romero J, Peiretti MAC. Amiodarone and hypokalemia. A dangerous combination. Intl J Cardiol 1986;13:365-8
   PubMed Web of Science ®Google Scholar
• Sclarovsky S, Lewin RF, Kracoff O, Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J 1983;105:6-12
   PubMed Web of Science ®Google Scholar
• Jafari-Fesharaki M, Scheinman MM. Adverse effects of amiodarone. PACE 1998;21(Pt I):108-20
   Google Scholar
• Appelbaum D, Halperin E. Asystole following a conventional therapeutic dose of lidocaine. Am J Emerg Med 1986;4:143-5
   PubMed Web of Science ®Google Scholar
• Manyari-Ortega DE, Brennan FJ. Lidocaine-induced cardiac asystole. Chest 1978;74:227-9
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Cines M, Marshall J. Torsades de pointes with administration of high-dose intravenous d-sotalol to a patient with congestive heart failure. Pharmacotherapy 1997;17:830-1
   PubMed Web of Science ®Google Scholar
• Link MS, Foote CB, Sloan SB, Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis. Chest 1997;112:556-7
   PubMed Web of Science ®Google Scholar
• Marinella MA, Burdette SD. Visual diagnosis in emergency medicine. Hypokalemia-induced QT interval prolongation. J Emerg Med 2000;19(4):375-6
   PubMed Web of Science ®Google Scholar
• Chvilicek JP, Hurlbert BJ, Hill GE. Diuretic-induced hypokalemia inducing torsades de pointes. Can J Anaesth 1995;42(12):1137-9
   PubMed Web of Science ®Google Scholar
• Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidmiol Drug Saf 2002;11:477-86
   PubMed Web of Science ®Google Scholar
• Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-36
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Corken A, Gallo-Torres H, Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions. Am J Gastroenterol 2001;96:1698-703
   PubMed Web of Science ®Google Scholar
• Honig PK, Wortham DC, Zamani K, Terfenadine-ketoconazole interactions. JAMA 1993;269:1513-18
   PubMed Web of Science ®Google Scholar
• Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003;45:415-27
   PubMed Web of Science ®Google Scholar
• Charbit B, Albaladejo P, Funck-Bretano C, Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-100
   PubMed Web of Science ®Google Scholar
• Charbit B, Alvarez JC, Dasque E, Droperidol and ondansetron-induced QT interval prolongation. Anesthesiology 2008;109:206-12
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Corken A, Gallo-Torres H, Postmarketing reports if QT prolongation with ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions. Am J Gastroenterol 2001;96:1698-703
   PubMed Web of Science ®Google Scholar
• Turner S, Mathews L, Pandharipande P, Thompson R. Dolasetron-induced torsades de pointes. J Clin Anesth 2007;19:622-5
   PubMed Web of Science ®Google Scholar
• Habib AS, Gan TJ. Food and drug administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003;96:1377-9
   PubMed Web of Science ®Google Scholar
• Product Information: Propulsid®, cisapride. Janssen Pharmaceutica, Inc., Titusville, NJ; 2000
   Google Scholar
• Kies SJ, Pabelick CM, Hurley HA, Anesthesia for patients with congenital long QT syndrome. Anesthesiology 2005;102:204-10
   PubMed Web of Science ®Google Scholar
• Booker PD, Whyte SD, Ladusans EJ. Long QT syndrome and anaesthesia. British Journal of Anaesthesia 2003;90(3):349-66
   PubMed Web of Science ®Google Scholar
• Kuenszberg E, Loeckinger A, Kleinsasser A, Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000;17:662-4
   PubMed Web of Science ®Google Scholar
• Schmeling WT, Warltier DC, McDonald DJ, Prolongation of the QT interval by enflurane, isoflurane, and alothane in humans. Anesth Analg 1991;72:137-44
   PubMed Web of Science ®Google Scholar
• McConachie I, Keaveny JP, Healy TE, Effect of anaeshtesia on the QT interval. Br J Anaesth 1983;55:361-4
   PubMedGoogle Scholar
• Saarnivaara L, Lindgren L. Prolongation of QT interval during induction of anaesthesia. Acta Anaesth Scand 1982;27:126-30
   Web of Science ®Google Scholar
• Kleinsasser A, Keunszberg E, Loeckinger A, Sevoflurance, but not propofol, significantly prolongs the QT interval. Anesth Analg 2000;90:25-7
   PubMed Web of Science ®Google Scholar
• Kleinsasser A, Loeckinger A, Linder KH, Reversing sevoflurane-associated QTc prolongation by changing to propofol. Anaesthesia 2001;56:248-50
   PubMed Web of Science ®Google Scholar
• Michaloudis DG, Kanakoudis FS, Xatzikraniotis A, Bischinotis TS. The effects of midazolam followed by administration of either vecuronium or atracurium on the QT interval in humans. Eur J Anaesthesiol 1995;12:577-83
   PubMed Web of Science ®Google Scholar
• Lischke V, Wilke HJ, Probst S, Prolongation of the QT interval during induction of anesthesia in patients with coronary artery disease. Acta Anaesthesiol Scand 1994;38:144-8
   PubMed Web of Science ®Google Scholar
• Callahan ML, Nichols AB, Sweet RB. Anesthetic management of prolonged QT interval syndrome. Anesthesiology 1977;47:67-9
   PubMed Web of Science ®Google Scholar
• Beccaria E, Brun S, Gaita F, Torsades de pointe during an atropine sulfate test in a patient with congenital long QT syndrome. Cardiologia 1989;34:1039-43
   PubMedGoogle Scholar
• Saarnivaara L, Simoa M. Effects of four anticholinesterase-anticholinergic combinations and tracheal extubation on QTc interval of the ECK, heart rate and arterial pressure. Acta Anesthesiol Scand 1998;42:460-3
   PubMed Web of Science ®Google Scholar
• Medak R, Benumof jl. Perioperatve management of the prolonged QT interval syndrome. Br J Anaesth 1983;55:361-4
   PubMed Web of Science ®Google Scholar
• Carlock FJ, Brown M, Brown EM. Isoflurane anesthesia for a patient with long QT syndrome. Can Anesth Soc J 1984;31:83-5
   PubMedGoogle Scholar
• Gallagher JD, Weindling SN, Anderson G, Fillinger MP. Effects of sevoflurane on QT interval in a patient with congenital long QT syndrome. Anesthesiology 1998;89:1569-73
   PubMed Web of Science ®Google Scholar
• Wilton NCT, Hantler CB. Congenital long QT syndrome: changes in QT interval during anesthesia with thiopental, vecuronium, fentanyl, and isoflurane. Anesth Analg 1987;66:357-60
   PubMed Web of Science ®Google Scholar
• Saitz R. Treatment of alcohol and other drug dependence. Liver Transpl 2007;13(11 Suppl 2):S59-64
   PubMed Web of Science ®Google Scholar
• Lugo RA, MacLaren R, Cash J, Enteral methadone to expedite fentanyl discontinuation and prevent opioid abstinence syndrome in the PICU. Pharmacotherapy 2001;21(12):1566-73
   PubMed Web of Science ®Google Scholar
• Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System(AERS). Pharmacoepidemiol Drug Saf 2009;18:512-8
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Rowan SB, Schmitter J, Bucher Bartelson. Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 2007;26(4):79-85
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Martin J, Stimmel B, QTc interval screening in methadone treatment. Ann Intern Med 2009;150:387-95
   PubMed Web of Science ®Google Scholar
• Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T prolongation and torsades de pointes. Am J Health Syst Pharm 2009;66:825-33
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy 2003;23(6):802-5
   PubMed Web of Science ®Google Scholar
• McCusker J, Cole M, Abrahamowicz M, Delirium predicts 12-month mortality. Arch Intern Med 2002;162:457-63
   PubMed Web of Science ®Google Scholar
• Dubois MJ, Bergeron N, Dumont M, Delirium in an intensive care unit: a study of risk factors. Intensive Care Med 2001;27:1297-304
   PubMed Web of Science ®Google Scholar
• Dial S, Payne J. Managing delirium in the intensive care unit. Clin Pulm Med 2002;9:260-6
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999;156:1-20
   Web of Science ®Google Scholar
• Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer–their spouses/caregivers, and their nurses. Psychosomatics 2002;43:183-94
   PubMed Web of Science ®Google Scholar
• Weller R, Preskorn SH. Psychotropic drugs and alcohol: pharmacokinetic and pharmacodynamic interactions. Psychosomatics 1984;25:301-9
   PubMed Web of Science ®Google Scholar
• Kitayama H, Kiuchi K, Nejima J, Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 1999;55(4):259-62
   PubMed Web of Science ®Google Scholar
• Reilly JG, Ayis SA, Ferrier IN, QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355(9209):1048-52
   PubMed Web of Science ®Google Scholar
• Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996;93(4):311-3
   PubMed Web of Science ®Google Scholar
• Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs. haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004;30:444-9
   PubMed Web of Science ®Google Scholar
• Sharma ND, Rosman HS, Padhi ID, Torsades de pointed associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998;81:238-40
   PubMed Web of Science ®Google Scholar
• Dewan V, Roth BA. Antipsychotic-induced QTc interval prolongation. Can J Psychiatry 2004;49:646
   PubMed Web of Science ®Google Scholar
• Gurovich I, Vempaty A, Lippman S. QTc prolongation: chlorpromazine and high dose olanzapine. Can J Psychiatry 2003;48:348
   PubMed Web of Science ®Google Scholar
• Dineen S, Withrow K, Voronovitch L, QTc prolongation and high-dose olanzapine. Psychosomatics 2003;44:174-5
   PubMed Web of Science ®Google Scholar
• Nandagopal JJ, Craig JM, Lippmann S. QTc prolongation: possible association with risperidone and/or haloperidol. Psychosomatics 2000;41:63-5
   PubMedGoogle Scholar
• Chang JH, Weng TI, Fang CC. Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning. Am J Emerg Med 2009;27(8):1016
   PubMed Web of Science ®Google Scholar
• Van Noord, Straus SMJM, Sturkenboom MCJM, Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009;29(1):9-15
   PubMed Web of Science ®Google Scholar
• Huang BH, Hsia CP, Chen CY. Sulpiride induced torsade de pointes. Int J Cardiol 2007;118(3):100-2
   Google Scholar
• Yeragani VK, Pohl R, Jampala VC, Effects of nortriptyline and paroxetine on QT variability in patients with panic disorder. Depress Anxiety 2000;11:126-30
   PubMed Web of Science ®Google Scholar
• The Cardiac Arrhythmia Pilot Study (CAPS) Investigators Effects of encainide, flecainide, imipramine, and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol 1988;61:501-9
   PubMed Web of Science ®Google Scholar
• Bolognesi R, Tsialtas D, Vasini P, Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am J Cardiol 1997;79:242-3
   PubMed Web of Science ®Google Scholar
• Pacher P, Ungvari Z, Nanasi PP, Speculations on difference between tricyclic and selective serotonin reuptake inhibitor and antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999;6:469-80
   PubMed Web of Science ®Google Scholar
• Rajamani S, Eckhardt LL, Klemens CA, Drug-induced long QT syndrome:hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006;149:481-9
   PubMed Web of Science ®Google Scholar
• Witchel HJ, Pabbathi VK, Hofmann G, Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002;512:59-66
   PubMed Web of Science ®Google Scholar
• Wilting I, Smals OM, Holwerda NJ, QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry 2006;163:325
   PubMed Web of Science ®Google Scholar
• Varriale P. Fluoxetine (Prozac) as a cause of QT prolongation. Arch Intern Med 2001;161:612
   PubMed Web of Science ®Google Scholar
• Kanjanauthai S, Kanluen T, Chareonthaitawee P. Citalopram induced torsades de pointes, a rare life threatening side effect. Int J Cardiol 2008;131(1):e33-4
   PubMed Web of Science ®Google Scholar
• Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005;20:243-51
   PubMed Web of Science ®Google Scholar
• Brown CS, Farmer RG, Soberman JE, Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet 2004;43:33-56
   PubMed Web of Science ®Google Scholar
• Liu BA, Juurlink DN. Drugs and the QT interval-caveat doctor. N Engl J Med 2004;351:1053-56
   PubMed Web of Science ®Google Scholar
• Loga S, Curry S, Lader M. Interaction of chlorpromazine and nortriptyline in patients with schizophrenia. Clin Pharmacokinet 1981;6:454-62
   PubMed Web of Science ®Google Scholar
• Simko J, Csilek A, Karaszi J, Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection 2008;36:194-206
   PubMed Web of Science ®Google Scholar
• Schaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35:197-200
   PubMed Web of Science ®Google Scholar
• Haverkamp W, Eckardt L, Monnlg G, Clinical aspects of ventricular arrhythmias associated with QT prolongation. Eur Heart J Suppl 2001;3 (Suppl K):K81-8
   Google Scholar
• Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001;21(3):301-19
   PubMed Web of Science ®Google Scholar
• Katapadi K, Kostandy G, Katapadi M, A review of erythromycin-induced malignant tachyarrythmia-torsades de pointes. A case report. Angiology 1997;48:821-6
   PubMed Web of Science ®Google Scholar
• Harris S, Hilligoss DM, Colangelo PM, Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995; 58:310-5
   PubMed Web of Science ®Google Scholar
• Kang J, Wang L, Chen XL, Interactions of a series of fluoroquinolone antibacterial drugs with the human cardia K+ channel HERG. Mol Pharmacol 2001;59:122-6
   PubMed Web of Science ®Google Scholar
• Owens RCJ, Ambrose PG. Torsdaes de pointed associated with ciprofloxacin, ofloxacin levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2002;22(5):663-72
   PubMed Web of Science ®Google Scholar
• Frothingham R. Ciprofloxacin associated with a much lower rate of torsades de pointes than levofloxacin, gatifloxacin, or moxifloxacin in the FDA spontaneous reporting database [abstract L-589]. In: Program and abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington DC). American Society for Microbiology, Washington, DC; 2005. p. 392
   Google Scholar
• Dupont H, Timsit JF, Souweine B, Torsades de pointed probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996;15:350-1
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Eng J Med 2006;354 (13):1352-61
   Google Scholar
• Product information: Avelox®, moxifloxacin. Bayer Corp., Wayne NJ; 2009
   Google Scholar
• Chen X, Cass JD, Bradley JA, QT prolongation and proarrhythmia by moxifloxacin:concordance of preclinical models in realtion to clinical outcome. Br J Pharmcacol 2005;146:792-9
   PubMed Web of Science ®Google Scholar
• Owens RC. QT prolongation with antimicrobial agents. Drugs 2004;64(10):1091-124
   PubMed Web of Science ®Google Scholar
• Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18:83-97
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Kuhn DM. Voriconazole-better chances for patients with invasive mycoses. Eur J Med Res 2002;7(5):242-56
   PubMed Web of Science ®Google Scholar
• Honig PK, Worham DC, Zamani K, The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993;53:630-6
   PubMed Web of Science ®Google Scholar
• Hunfeld NG, Westerman EM, Boswijk DJ, Quetiapine in overdosage:a clinical and pharmacokinetic analysis of 14 cases. Ther Drug Monit 2006;28(2):185-9
   PubMed Web of Science ®Google Scholar
• Isbister GK, Duffull SB. Quetiapine overdose: predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal. Int Clin Psychopharmacol 2009;24:174-80
   PubMed Web of Science ®Google Scholar
• Ngo A, Ciranni M, Olson KR. Acute quetiapine overdose in adults: A 5-year retrospective case series. Ann Emerg Med 2008;52:541-7
   PubMed Web of Science ®Google Scholar
• Hustey FM. Acute quetiapine poisoning. J Emerg Med 1999;17:995-7
   PubMed Web of Science ®Google Scholar
• Harmon TJ, Benitez JG, Krenzelok, Loss of consciousness from acute quetiapine overdosage. J Toxicol Clin Toxicol 1998;36:599-602
   PubMed Web of Science ®Google Scholar
• Balit CR, Isbister GK, Hackett LP, Quetiapine poisoning: a case series. Ann Emerg Med 2003;42:751-8
   PubMed Web of Science ®Google Scholar
• Henderson RA, Lane S, Henry JA. Life threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Hum Exp Toxicol 1991;10(1):59-62
   PubMed Web of Science ®Google Scholar
• Isbister GK, Bowe SJ, Dawson A, Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004;42:277-85
   PubMed Web of Science ®Google Scholar
• Personne M, Sjoberg G, Persson H. Citalopram overdose: review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997;35:237-40
   PubMed Web of Science ®Google Scholar
• Isbister GK, Friberg LE, Stokes B, Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med 2007;50:593-600
   PubMed Web of Science ®Google Scholar
• Scharko AM, Schumacher J. Prolonged QTc interval in a 14-year-old girl with escitalopram overdose. J Child Adolescent Psychopharmacology 2008;18(3):297-8
   PubMed Web of Science ®Google Scholar
• Van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009;54:404-8
   PubMed Web of Science ®Google Scholar
• Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007;64(2):192-7
   PubMed Web of Science ®Google Scholar
• Isbister GK. Electrocardiogram changes and arrythmias in venlafaxine overdose. Br J Clin Pharmacol 2009;67(5):572-6
   PubMed Web of Science ®Google Scholar
• Wilens TE, Stern TA, O'Gara PT. Adverse cardiac effects of combined neuroleptic ingestion and tricyclic antidepressant overdose. J Clin Psychopharmacol 1990;10(1):51-4
   PubMed Web of Science ®Google Scholar
• Zipes DP, Camm AJ, Borggrefe M, ; European Heart Rhythm Association, Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society. J Am Coll Cardiol 2006;48(5):e247-346
   PubMedGoogle Scholar
• Tzivoni D, Banai S, Schuger C, Treatment of torsades de pointes with magnesium sulfate. Circulation 1988;77:392-7
   PubMed Web of Science ®Google Scholar
• Gupta A, Lawrence AT, Krishnan K, Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153:891-9
   PubMed Web of Science ®Google Scholar
• Di Segni E, David D, Katzenstein M, Permanent overdrive pacing for the suppression of recurrent ventricular tachycardia in a newborn with long QT syndrome. J Electrocardiol 1980;13:189-92
   PubMed Web of Science ®Google Scholar
• Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002;112:58-66
   PubMed Web of Science ®Google Scholar
• Viskin S. Torsades de pointes. Curr Treat Options Cardiovasc Med 1999;1:187-95
   PubMedGoogle Scholar
• Sauer AJ, Moss AJ, McNitt S, Long QT syndrome in adults. J Am Coll Cardiol 2007;49:329-37
   PubMed Web of Science ®Google Scholar
• Schwartz, PJ, Priori SG, Spazzolini C, Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103:89-95
   PubMed Web of Science ®Google Scholar
• Patel C, Antzelevitch C. Pharmacologic approach to the treatment of long and short QT syndromes. Pharm Ther 2008;118:138-51
   PubMed Web of Science ®Google Scholar
• Zareba W, Moss AJ, Daubert JP, Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003;14:337-41
   PubMed Web of Science ®Google Scholar
• Daubert JP, Zareba W, Rosero SZ, Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome. Am J Heart 2007;153:S53-8
   PubMed Web of Science ®Google Scholar
• Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25:1612-5
   PubMed Web of Science ®Google Scholar
• Trohman RG, Kim MH, Pinski SL. Cardiac pacing: the state of the art. Lancet 2004;364:1701-19
   PubMed Web of Science ®Google Scholar
• Arizona Center for Education and Research on Therapeutics. Available at: http://www.azcert.org/index.cfm. [Last accessed 5 February 2010]
   Google Scholar